WO2002098346A3 - Method and pharmaceutical composition for the treatment of multiple sclerosis - Google Patents

Method and pharmaceutical composition for the treatment of multiple sclerosis Download PDF

Info

Publication number
WO2002098346A3
WO2002098346A3 PCT/IL2002/000337 IL0200337W WO02098346A3 WO 2002098346 A3 WO2002098346 A3 WO 2002098346A3 IL 0200337 W IL0200337 W IL 0200337W WO 02098346 A3 WO02098346 A3 WO 02098346A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
multiple sclerosis
pharmaceutical composition
diseases
progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2002/000337
Other languages
French (fr)
Other versions
WO2002098346A2 (en
Inventor
Nathan Karin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rappaport Family Institute for Research in the Medical Sciences
Original Assignee
Rappaport Family Institute for Research in the Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rappaport Family Institute for Research in the Medical Sciences filed Critical Rappaport Family Institute for Research in the Medical Sciences
Priority to EP02722648A priority Critical patent/EP1572065A2/en
Publication of WO2002098346A2 publication Critical patent/WO2002098346A2/en
Anticipated expiration legal-status Critical
Publication of WO2002098346A3 publication Critical patent/WO2002098346A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and pharmaceutical compositions are disclosed, effective in breaking-down immunological tolerance the CXC chemokine interferon gamma-inducible protein 10 (IP-10), resulting in the generation of self specific immunity to IP-10, for the treatment of diseases, such as autoimmune diseases, in which IP-10 plays a pivotal role in disease onset and/or progression, e.g., in multiple sclerosis (MS).
PCT/IL2002/000337 2001-06-05 2002-04-30 Method and pharmaceutical composition for the treatment of multiple sclerosis Ceased WO2002098346A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02722648A EP1572065A2 (en) 2001-06-05 2002-04-30 Method and pharmaceutical composition for the treatment of multiple sclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/873,415 2001-06-05
US09/873,415 US20030166589A1 (en) 2001-06-05 2001-06-05 Method and pharmaceutical composition for the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
WO2002098346A2 WO2002098346A2 (en) 2002-12-12
WO2002098346A3 true WO2002098346A3 (en) 2013-10-31

Family

ID=25361583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000337 Ceased WO2002098346A2 (en) 2001-06-05 2002-04-30 Method and pharmaceutical composition for the treatment of multiple sclerosis

Country Status (3)

Country Link
US (1) US20030166589A1 (en)
EP (1) EP1572065A2 (en)
WO (1) WO2002098346A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1317285B1 (en) * 2000-08-18 2009-10-07 The Regents of the University of California Methods for treating demyelinating diseases
EP1411966A4 (en) * 2001-07-12 2005-06-01 Univ California METHOD FOR TREATING SECONDARY TISSUE DEGENERATION WITH INJURY OF THE CENTRAL NERVOUS SYSTEM
US20040096446A1 (en) * 2001-08-17 2004-05-20 Lane Thomas E. Methods for treating demyelinating diseases
FR2838444B1 (en) * 2002-04-10 2016-01-01 Neovacs NEW PEPTIDES AND THEIR THERAPEUTIC APPLICATION
US8563476B2 (en) 2002-11-15 2013-10-22 Morehouse School Of Medicine Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders
US20120263733A1 (en) * 2002-11-15 2012-10-18 Morehouse School Of Medicine Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
US7964194B2 (en) * 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
CA2534711A1 (en) * 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
US20050053600A1 (en) * 2003-09-09 2005-03-10 Lane Thomas E. Methods for treating rheumatoid arthritis
KR101374514B1 (en) * 2003-12-10 2014-03-13 메다렉스, 인코포레이티드 Ip-10 antibodies and their uses
CN101668774B (en) 2007-02-28 2013-06-26 诺维莫尼公司 Anti-ip-10 antibodies and methods of use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
EP2702076A1 (en) 2011-04-29 2014-03-05 Bristol-Myers Squibb Company Ip-10 antibody dosage escalation regimens
EP3134730A4 (en) * 2014-04-24 2018-01-17 Immusant Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines
WO2016081869A2 (en) 2014-11-21 2016-05-26 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
KR102630475B1 (en) 2015-11-30 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 Anti-human IP-10 antibody and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752886B1 (en) * 1993-08-26 1998-01-28 M&E BIOTECH A/S Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752886B1 (en) * 1993-08-26 1998-01-28 M&E BIOTECH A/S Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BALASHOV ET AL.: "CCRS + and CXCR3 + T Cells are Increased in Multiple Sclerosis and their Ligands MIP-1alpha and IP-10 are Expressed in Demyelinating Brain Lesions.", PNAS USA., vol. 96, June 1999 (1999-06-01), pages 6873 - 6878 *

Also Published As

Publication number Publication date
US20030166589A1 (en) 2003-09-04
EP1572065A2 (en) 2005-09-14
WO2002098346A2 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
EP2085096A3 (en) Novel composition and methods for the treatment of immune related diseases
WO2000053758A3 (en) Compositions and methods for the treatment of immune related diseases
BG104236A (en) Transgenous mammals producing oligosaccharides in their milk
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001079458A3 (en) Polypeptides having haloperoxidase activity
EP2039699A3 (en) Extractive methods for purifying sucralose
BR0214705A (en) Composition, use, method for prevention or treatment of neurodegenerative disease, and kit
EP1018517A3 (en) Binding agents to CD23 for treatment of inflammatory, autoimmune or allergic diseases
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
GB0111186D0 (en) Novel compounds
WO2002089738A3 (en) Proteomimetic compounds and methods
CA2368165A1 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO1999059617A3 (en) Immunoregulator
WO2004043397A3 (en) Compositions and methods for the treatment of rheumatoid arthritis
CA2210871A1 (en) Human dnase i variants
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases
ES2165792A1 (en) Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
WO2002000829A3 (en) A novel peptide--- human ftsh protein 16.83 and the polynucleotide coding this novel peptide
WO2001016319A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001075060A3 (en) A novel polypeptide, human cystein protease 9 and the polynucleotide encoding the polypeptide
WO2001075026A3 (en) A novel polypeptide, human eucaryotic acetyl transferase 10 and the polynucleotide encoding the polypeptide
WO2001075022A3 (en) A novel polypeptide, human eucaryotic acetyl transferase 12 and the polynucleotide encoding the polypeptide
WO2001075036A3 (en) A novel polypeptide, human immunophiline 14 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002722648

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002722648

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002722648

Country of ref document: EP